GLP-1 & Metabolic Psychiatry at AACAP Annual Meeting 2026
27 sessions on glp-1 & metabolic psychiatry · October 26–31, 2026, Atlanta, GA. Compare glp-1 & metabolic psychiatry at other meetings →
Tuesday, October 27
09:00–11:00 · Lecture
Next-Generation Therapies for Obesity and Associated Food-Related Aggression in Intellectual and Developmental Disabilities
Covers emerging treatment options for obesity and food-related aggression in people with intellectual and developmental disabilities.
14:00–16:00 · Lecture · Clinical Perspectives
Evidence-Based Strategies to Screen and Manage Endocrine and Metabolic Complications
Reviews screening and management of endocrine and metabolic complications of psychotropic medications in children and adolescents.
Wednesday, October 28
11:30–13:30 · Lecture · Clinical Perspectives
Managing Antipsychotic-Induced Weight Gain
Addresses approaches to managing weight gain associated with antipsychotic treatment in youth.
11:30–13:30 · Lecture · Clinical Perspectives
Managing Antipsychotic Medication Weight Gain in the Era of New-Generation Obesity Pharmacotherapy
Considers managing antipsychotic-related weight gain using newer obesity medications.
11:30–13:30 · Lecture · Clinical Perspectives
Prescribing GLP-1 Receptor Agonists in Pediatric Obesity: Practical Dosing and Monitoring Considerations
Provides practical guidance on dosing and monitoring GLP-1 receptor agonists for pediatric obesity.
11:30–13:30 · Lecture · Clinical Perspectives
Creating a Strong Foundation: Behavioral Strategies for Effective Pediatric Obesity Care
Outlines behavioral strategies that underpin effective pediatric obesity care.
15:00–17:00 · Lecture · Clinical Perspectives
GLP-1s: From Prescribing to Pop Culture
A talk on how GLP-1 receptor agonists have moved from clinical prescribing into popular culture, and what that means for clinicians working with eating disorders.
15:00–17:00 · Lecture · Clinical Perspectives
Benefits of GLP-1 Receptor Agonists in Adolescents With Obesity and Loss of Control Eating
Reviews potential benefits of GLP-1 receptor agonists for adolescents who have obesity along with loss of control eating.
15:00–17:00 · Lecture · Clinical Perspectives
The Risks Beneath the Hype: GLP-1 Use and Eating Disorders
Examines the risks associated with GLP-1 medication use in the context of eating disorders.
15:00–17:00 · Lecture · Clinical Perspectives
Eating Disorder Screening Prior to GLP-1 Receptor Agonist Initiation: Current Recommendations and Clinical Gaps
Covers current recommendations and gaps in screening for eating disorders before starting GLP-1 receptor agonists.
Symposium · Clinical Perspectives
Clinical Pathways for Antipsychotic-Associated Weight Gain in Youth: GLP-1–Based Treatment, Multimodal Care, and Behavioral Interventions
Musa Yilanli · Eileen A. Chaves · Zhanna Elberg · Perihan Esra Guvenek-Cokol · Amy L. Christison · Hiba Salhah
Clinical session laying out care pathways for antipsychotic-associated weight gain in youth, including where GLP-1 receptor agonists, multimodal care, and behavioral interventions fit.
Symposium · Clinical Perspectives
GLP-1 Receptor Agonists and Eating Disorders: Emerging Evidence, Risks, and Clinical Considerations
Felicia G. Gallucci · Jennifer L. Derenne · Aisa M. Moreno-Megui · Alexandra N. Coppa · Jessica D. Leuchter
Session on the intersection of GLP-1 receptor agonists and eating disorders in youth — emerging evidence, risks of misuse, and clinical considerations for prescribers.
Posters (3)
- Pharmacovigilance Analysis of Psychiatric Adverse Events Associated With Semaglutide and Liraglutide — Qiyang Pan et al.
- Weight and Metabolic Outcomes Following GLP-1 Receptor Agonist Initiation in Youth Receiving Atypical Antipsychotics — Lucia Liu et al.
- Polygenic Risk and BMI Among Antipsychotic-Treated Youth — Samuel Palmer et al.
Thursday, October 29
08:00–10:00 · Lecture
Metformin for Overweight and Obese Children With Bipolar Spectrum Disorders Treated With Second-Generation Antipsychotics: A Large Pragmatic Study
Presents a large pragmatic study of metformin for weight gain in children with bipolar spectrum disorders on second-generation antipsychotics.
Antipsychotic Prescribing · Bipolar Disorder · Child & Adolescent
08:00–10:00 · Lecture
GLP-1 Receptor Agonists In Youth with Mental Disorders: Evidence-Based Application and Development/Repurposing as Psychiatric Drugs
Reviews evidence for using GLP-1 receptor agonists in youth with mental disorders and their potential repurposing as psychiatric treatments.
08:00–10:00 · Lecture
Novel Models of Integrated Care: Promoting Healthy Weight in Youth With Mental Health Conditions
Gail L. Daumit · Rheanna Platt
Describes integrated care models aimed at supporting healthy weight in youth with mental health conditions.
10:00–12:00 · Lecture
Metabolic Monitoring Among Children and Youth Prescribed Second-Generation Antipsychotic Medication in a Large Healthcare System Network
Bonnie T. Zima · Alexandra M. Klomhaus · Joshua J. Lee · Juliet Edgcomb
Reports how often metabolic monitoring occurs in youth prescribed second-generation antipsychotics within a large healthcare system.
16:00–18:00 · Lecture
Critical Literature Updates in Pediatric Catatonia, Neurodevelopmental Disorders, Obesity, and Girls’ Sexual and Reproductive Mental Health
Literature update spanning pediatric catatonia, neurodevelopmental disorders, obesity, and girls' sexual and reproductive mental health.
Autism & Neurodevelopmental Disorders · Catatonia · Perinatal & Women's Mental Health
Course · Institute
Research Institute: Cardiometabolic Connections With Mind, Medication, and Models of Care in Child and Adolescent Psychiatry
Benjamin I. Goldstein · Paul E. Croarkin · Daphne Korczak · Melissa P. DelBello · Roger S. McIntyre · Judy Luu · Gail L. Daumit
Research institute on the two-way links between psychiatric illness and cardiometabolic health in youth — including medication-related weight gain, insulin resistance, and dyslipidemia — and how that science should inform treatment planning.
Friday, October 30
Posters (2)
- Adolescent Experiences of Reward, Cravings, and Cannabis Use During GLP-1 Treatment in a Pediatric Weight Management and Diabetes Program — Sanjana Baliga et al.
- GLP-1 Receptor Agonists and Transcranial Magnetic Stimulation for Adolescent Mood Disorders, Obesity, and Substance-Use Vulnerability: A Focused Review — Darius M. Hardie et al.
Saturday, October 31
10:00–12:00 · Lecture · Clinical Perspectives
Complexity of Pediatric Obesity Management: When Does Treatment Help or Harm?
Examines the benefits and potential harms of treating pediatric obesity.
10:00–12:00 · Lecture · Clinical Perspectives
Navigating Complexity in Pediatric Weight Loss Therapy
Covers the complexities of weight loss therapy in pediatric patients.
10:00–12:00 · Session
Pediatric Medicine Updates: Expanding Pediatric Obesity Treatment Amid Controversies in Weight Management
Amy Lynn Meadows · Amy Kim · Nazeeha J. Micciche · Raul J. Martinez-McFaline · Elizabeth Wassenaar · Rachana Shah
Posters (1)
- Prevalence of Food Security and Healthy Water Intake Among Medicaid-Insured Youth at Time of Antipsychotic Drug Initiation — Andrea Natalia M. Orpia et al.
Other topics at this meeting
Child & Adolescent 1361Autism & Neurodevelopmental Disorders 272Diverse & Underserved Populations 231Practice, Policy & Workforce 171Psychotherapy 166Education & Training 156Digital Psychiatry & AI 149Measurement-Based Care & Diagnosis 145ADHD 135Neuroscience & Mechanisms 124PTSD & Trauma 114Suicide & Self-Harm 110